Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

Claveau, Jean-Sébastien; Murray, David; Dispenzieri, Angela; Kapoor, Prashant; Binder, Moritz; Buadi, Francis K.; Dingli, David; Fonder, Amie; Gertz, Morie A.; Gonsalves, Wilson I.; Hayman, Suzanne R.; Hobbs, Miriam; Hwa, Yi L.; Kourelis, Taxiarchis; Lacy, Martha Q.; Leung, Nelson; Lin, Yi; Warsame, Rahma; Kyle, Robert A.; Rajkumar, Vincent; Kumar, Shaji

doi:10.1038/s41375-022-01779-8

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Joinpoint Survival Model is a continuation of the Cox proportional hazards model for survival [10][11][12]. It can be used to analyze both Relative Survival and Cause-Specific Survival.…”

Section: Methodsmentioning

confidence: 99%

“…High-risk cytogenetics such as t(4;14), t(14;16), and del(17p) are now incorporated into risk stratification systems and influence staging [ 10 ]. Quantifying the plasma cell population in the bone marrow has also been crucial to determining an accurate response [ 11 ]. Additionally, the IMWG has developed new criteria to define disease response, emphasizing the ways to assess minimal residual disease (MRD), which is based on findings in the bone marrow flow cytometry and/or next-generation sequencing (NGS), along with imaging (PET/CT) [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Updates in Multiple Myeloma Treatment and Management

Nieto,

Hedjar,

Locke

et al. 2023

J Clin Haematol

View full text Add to dashboard Cite

Introduction: During the past two decades, new therapeutic agents have greatly improved the treatment landscape in multiple myeloma (MM). Treatments such as proteasome inhibitors, immunomodulatory agents, targeted monoclonal antibody therapy, and chimeric antigen receptor (CAR) T-cell therapy have improved outcomes with less toxicity. Advances in laboratory testing have accompanied this change, performing faster and more accurate assessments of treatment response. Despite these advances, however, disparities in MM outcomes persist. Objective: The purpose of this study was to review epidemiological trends in MM over the past two decades and to identify disparities that may impact MM identification and survival. Methods: Retrospective analysis was conducted on adult patients diagnosed with MM between the years 2000-2019 using the November 2021 Surveillance, Epidemiology, and End Results (SEER) program database. Joinpoint models were used to calculate annual percent changes (APCs) and average annual percent change (AAPC). Results: There were a total of 111,328 diagnoses of MM extracted from the SEER database. Most patients were male (55.17%) and white (76.7%). Age-adjusted rate analysis found a significantly higher incidence among black patients compared to white patients. The APC between 2000-2015 was 1.46, and the APC between 2015-2019 was -1.34. Relative survival also increased from 2000 to 2014. The 5-year cancer survival in MM also increased at an average of 1.8% for every year after diagnosis. The annual probability of MM-related mortality at the 1-year mark also decreased from 28.5% in 2000 to 16.7% in 2018. Conclusion: Novel advances in MM therapeutic agents and diagnostic testing have paved the way for significant improvements in patient survival outcomes. Disparities persist along racial lines. Further research is needed to evaluate responses to specific MM treatment in the age of newly developed targeted therapies to overcome these disparities.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Analysis of Updates in Multiple Myeloma Treatment and Management

Nieto,

Hedjar,

Locke

et al. 2023

J Clin Haematol

View full text Add to dashboard Cite

show abstract

“…When compared with standard bone marrow derived MRD assessment techniques, intact protein MS can also provide valuable information. Several studies have employed both methods for disease assessment, generally demonstrating that patients who test negative using both methods tend to have the most favorable outcomes [71 ▪▪ ,72 ▪ ,73 ▪ ,74–79]. However, due to small sample sizes and inconsistent testing at different time points, we currently lack compelling data to directly compare their prognostic performance.…”

Section: Mass Spectrometrymentioning

confidence: 99%

Measurable residual disease in peripheral blood in myeloma: dream or reality

Kubicki,

Derman,

Dytfeld

et al. 2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review Therapeutic advancements in multiple myeloma have led to increasingly deeper and more durable responses, creating a need for highly sensitive and applicable techniques for measurable residual disease (MRD) assessment. Bone marrow assays can deeply assess for MRD, but it is not conducive to performing frequent and dynamic evaluations, which may be needed for MRD-adapted treatment approaches. Recently, numerous techniques for MRD assessment in peripheral blood have come under investigation, and their integration into routine clinical practice is eagerly anticipated. Recent findings The identification of circulating tumor cells (CTCs), evaluation of cell-free DNA, and measuring monoclonal protein concentration with mass spectrometry are promising research areas for assessing myeloma in peripheral blood. CTCs assessment and cell-free DNA may carry prognostic significance, but they lack the sensitivity of bone marrow-based techniques. Mass spectrometry has already been implemented in clinical practice in certain centers, but its full potential has yet to be fully realized. This review focuses on recent developments in these fields, emphasizing the potential future roles of these assessments. Summary MRD assessment in peripheral blood is still in the development stage but holds promise for not only complementing bone marrow based evaluations but also potential for improving sensitivity.

show abstract

Measurable Residual Disease and Decision-Making in Multiple Myeloma

Derman,

Fonseca

2024

Hematology/Oncology Clinics of North America

View full text Add to dashboard Cite

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

Cited by 5 publications

References 15 publications

Analysis of Updates in Multiple Myeloma Treatment and Management

Analysis of Updates in Multiple Myeloma Treatment and Management

Measurable residual disease in peripheral blood in myeloma: dream or reality

Measurable Residual Disease and Decision-Making in Multiple Myeloma

Contact Info

Product

Resources

About